Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

Proposed Revised Criteria for the Classification of Acute Myeloid Leukemia

1985 • 2,981 citations

The Central Role of CD4+ T Cells in the Antitumor Immune Response

1998 • 1,332 citations

Acute Myeloid Leukemia

1999 • 1,211 citations

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

2008 • 883 citations

Mediation by HLA-DM of dissociation of peptides from HLA-DR

1995 • 555 citations

Intracellular transport of class II MHC molecules directed by invariant chain

1990 • 548 citations

Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding

1990 • 486 citations

Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain

1991 • 326 citations

Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways

1990 • 303 citations

Specificity of T-cell alloreactivity

2007 • 236 citations

Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules.

1992 • 197 citations

Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches

2006 • 192 citations

The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy.

1994 • 184 citations

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity

1997 • 168 citations

Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro–transcribed MUC1 RNA

2004 • 166 citations

Association Between HLA-DM and HLA-DR In Vivo

1996 • 149 citations

Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions

2006 • 103 citations

Modulation of the Major Histocompatibility Complex Class II–Associated Peptide Repertoire by Human Histocompatibility Leukocyte Antigen (Hla)-Do

2000 • 89 citations

Germinal Center B Cells Regulate Their Capability to Present Antigen by Modulation of HLA-DO

2002 • 80 citations

Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.

2005 • 74 citations

Class II-Associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical Outcome

2004 • 64 citations

Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines

2004 • 50 citations

Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4+ T Cells Whether or Not They Are Silenced for Invariant Chain

2006 • 49 citations

Characterization of HLA-DR antigens on leukaemic cells.

1982 • 45 citations

Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells

2000 • 45 citations

Immunological weapons against acute myeloid leukaemia

2002 • 37 citations

The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes

2007 • 37 citations

Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells

2005 • 35 citations

Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins

1996 • 31 citations

An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia

2006 • 30 citations

MHC Class II Presentation of Endogenous Tumor Antigen by Cellular Vaccines Depends on the Endocytic Pathway but not H2‐M

2000 • 30 citations

Development of a whole cell vaccine for acute myeloid leukaemia

2005 • 21 citations

Characterization of intracellular HLA-DR, DM and DO profile in K562 and HL-60 leukemic cells

2008 • 12 citations

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity

1997 • 11 citations

Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine

2007 • 10 citations